Get the Stockscreener App
14.49
2.42%
-0.36
After Hours:
14.49
Anika Therapeutics Inc stock is traded at $14.49, with a volume of 26,934.
It is down -2.42% in the last 24 hours and up +3.43% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$14.85
Open:
$14.77
24h Volume:
26,934
Relative Volume:
0.39
Market Cap:
$196.90M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-2.858
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-0.14%
1M Performance:
+3.43%
6M Performance:
-11.10%
1Y Performance:
-47.48%
1-Day Range:
$14.43
$15.04
1-Week Range:
$14.27
$15.13
52-Week Range:
$12.83
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.49 | 196.90M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Is the Options Market Predicting a Spike in Anika Therapeutics Stock? - TradingView
Invesco Ltd. Has $452,000 Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Anika Therapeutics (ANIK) Projected to Post Quarterly Earnings on Friday - Defense World
Envestnet Asset Management Inc. Lowers Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Geode Capital Management LLC Has $5.32 Million Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
JPMorgan Chase & Co. Raises Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika to Issue First Quarter 2025 Financial Results on Friday, M - GuruFocus
Anika Therapeutics to Announce First Quarter 2025 Financial Results on May 9, 2025 - Nasdaq
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 - GlobeNewswire
Anika Earnings Preview: Joint Preservation Giant Reveals Q1 2025 PerformanceKey Metrics to Watch - Stock Titan
Anika Therapeutics (NASDAQ:ANIK) Upgraded at B. Riley - Defense World
B. Riley Initiates Coverage on Anika Therapeutics (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript - MSN
B. Riley Initiates Anika Therapeutics at Buy With $21 Price Target - marketscreener.com
Anika Therapeutics (ANIK) Receives 'Buy' Rating with $21 Target from B. Riley Analyst | ANIK Stock News - GuruFocus
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Purchased by Wellington Management Group LLP - Defense World
Viscosupplementation Market Is Booming Worldwide 2025-2032 | - openPR.com
Arrowstreet Capital Limited Partnership Has $979,000 Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by American Century Companies Inc. - Defense World
Anika Therapeutics announces COO departure, streamlines management By Investing.com - Investing.com Canada
Anika Therapeutics announces COO departure, streamlines management - Investing.com
Anika Therapeutics Announces COO Departure and Role Elimination - TipRanks
Viscosupplementation Market Outlook: Growth Drivers - openPR.com
Anika Therapeutics stock hits 52-week low at $13.7 - Investing.com Australia
Anika Therapeutics stock hits 52-week low at $13.7 By Investing.com - Investing.com South Africa
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Anika Grants 3,800 Share Options to New Hire: Key Details Revealed - Stock Titan
Anika Therapeutics, Inc. (NASDAQ:ANIK) Position Trimmed by HighTower Advisors LLC - Defense World
Are Options Traders Betting On A Big Move In Anika Therapeutics (ANIK) Stock? - Barchart.com
Are Options Traders Betting on a Big Move in Anika Therapeutics (ANIK) Stock? - TradingView
Viscosupplementation Market Is Booming Worldwide | Anika - openPR.com
Europe Viscosupplementation Market Projected To Witness - openPR.com
Anika Therapeutics stock hits 52-week low at $14.9 By Investing.com - Investing.com South Africa
Anika Therapeutics stock hits 52-week low at $14.9 - Investing.com India
How the (ANIK) price action is used to our Advantage - news.stocktradersdaily.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock Position Reduced by Charles Schwab Investment Management Inc. - Defense World
Hammertoe Solution Market Size, Trends 2031 By Key Players- - openPR.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Bank of New York Mellon Corp - Defense World
Europe Viscosupplementation Market Set to Witness Significant - openPR.com
Reviewing Anika Therapeutics (NASDAQ:ANIK) and InspireMD (NYSE:NSPR) - Defense World
Anika Therapeutics Faces Financial Strain Amid Geopolitical Tensions and Supply Chain Disruptions - TipRanks
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
| Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):